The image contains multiple graphs analyzing the effect of treatments on tumor growth and immune response in an E 0771 breast cancer model. Panel A shows a timeline of treatments and tumor measurements. Panels B to E present individual tumor growth curves for different treatment groups: vehicle, I g G 2 a, anti-C T L A-4, 3.2.16, and a combination of anti-C T L A-4 and 3.2.16. Panel F displays m R N A expression levels in tumors treated with vehicle or 3.2.16, with significant differences marked. Panels G to L show flow cytometry analysis of immune cell populations in tumors, including tumor-infiltrating leukocytes, T cells, N K cells, tumor-associated macrophages, myeloid-derived suppressor cells, and tumor cells expressing P D-L 1. Each graph includes individual values and means with statistical significance indicated. All data is approximate.
Effect of treatment with 3.2.16 in the E0771 BrCa model. (A) C57BL/6 mice received an injection of E0771 cells into the MFP and were treated with vehicle or IgG2a, α-CTLA-4, 3.2.16, or α-CTLA-4 + 3.2.16. (B–E) For each treatment group, individual tumor growth curves are presented. The number of mice in each group that achieved a CR on day 27 is indicated. (F) Tumors from mice treated with vehicle or 3.2.16 were analyzed for mRNA expression, shown as the mean + SD (n = 5). *P < 0.05 by Student’s t test. (G-L) Mice with 150-mm3 E0771 tumors in the MFP were treated with vehicle, α-CTLA-4, 3.2.16, or α-CTLA-4 + 3.2.16 (combination) and analyzed by flow cytometry. The percentage of CD45+ TILs (G), CD45+CD3+ T cells (H), CD45+CD3-NK1.1+ IFNγ+ NK cells (I), CD45+CD11b+ F4/80+ TAMs (J), CD45+CD11b+Ly6G+ MDSCs (K), and CD45−CD3-PDL1+ tumor cells (L) were determined. Data are presented as individual values and mean (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by one-way ANOVA with Dunnett’s post-test. TILs, tumor-infiltrating leukocytes.